<DOC>
	<DOCNO>NCT03017885</DOCNO>
	<brief_summary>This active surveillance include NSCLC patient treat nintedanib per inclusion/exclusion criterion approximately 20 selected center confirm 100 patient treated nintedanib include baseline characteristic 100 additional patient ( many patient nintedanib group &lt; 100 ) plan treat single agent docetaxel collect centre time frame , maximum two year , whichever occurs first</brief_summary>
	<brief_title>Post Marketing Surveillance Nintedanib Indian Patients With Non-small Cell Lung Cancer ( NSCLC ) After First-line Therapy</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Patients â‰¥18 year age locally advance and/or metastatic NSCLC stage IIIB IV , recurrent NSCLC adenocarcinoma histology relapse failure first line chemotherapy newly prescribe nintedanib accord package insert Willing provide inform consent Patients visit/contact possible planned period active surveillance Patients take nintedanib participation study Patients positive endothelial growth factor receptor mutation Patients positive anaplastic lymphoma kinase rearrangements Patients participate clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>